View Item 

Show simple item record

The implications of baseline bone‐health assessment at initiation of androgen‐deprivation therapy for prostate cancer
dc.contributor.authorKirk, Peter S.
dc.contributor.authorBorza, Tudor
dc.contributor.authorShahinian, Vahakn B.
dc.contributor.authorCaram, Megan E.V.
dc.contributor.authorMakarov, Danil V.
dc.contributor.authorShelton, Jeremy B.
dc.contributor.authorLeppert, John T.
dc.contributor.authorBlake, Ryan M.
dc.contributor.authorDavis, Jennifer A.
dc.contributor.authorHollenbeck, Brent K.
dc.contributor.authorSales, Anne
dc.contributor.authorSkolarus, Ted A.
dc.date.accessioned2018-04-04T18:47:10Z
dc.date.available2019-05-13T14:45:25Zen
dc.date.issued2018-04
dc.identifier.citationKirk, Peter S.; Borza, Tudor; Shahinian, Vahakn B.; Caram, Megan E.V.; Makarov, Danil V.; Shelton, Jeremy B.; Leppert, John T.; Blake, Ryan M.; Davis, Jennifer A.; Hollenbeck, Brent K.; Sales, Anne; Skolarus, Ted A. (2018). "The implications of baseline bone‐health assessment at initiation of androgen‐deprivation therapy for prostate cancer." BJU International 121(4): 558-564.
dc.identifier.issn1464-4096
dc.identifier.issn1464-410X
dc.identifier.urihttps://hdl.handle.net/2027.42/142891
dc.publisherWiley Periodicals, Inc.
dc.subject.otherbone
dc.subject.other#PCSM
dc.subject.other#ProstateCancer
dc.subject.otherfractures
dc.subject.otherosteoporosis
dc.subject.otherbone density
dc.subject.otherprostatic neoplasms
dc.subject.otheranti‐androgen effect
dc.titleThe implications of baseline bone‐health assessment at initiation of androgen‐deprivation therapy for prostate cancer
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142891/1/bju14075.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142891/2/bju14075_am.pdf
dc.identifier.doi10.1111/bju.14075
dc.identifier.sourceBJU International
dc.identifier.citedreferenceYee EF, White RE, Murata GH, Handanos C, Hoffman RM. Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy. J Gen Intern Med 2007; 22: 1305 – 10
dc.identifier.citedreferenceNational Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Prostate Cancer. Available at: https://seer.cancer.gov/statfacts/html/prost.html. Accessed January 2017.
dc.identifier.citedreferenceShahani S, Braga‐Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 2008; 93: 2042 – 9
dc.identifier.citedreferenceOstergren PB, Kistorp C, Bennedbaek FN, Faber J, Sonksen J, Fode M. The use of exercise interventions to overcome adverse effects of androgen deprivation therapy. Nat Rev Urol 2016; 13: 353 – 64
dc.identifier.citedreferenceWei JT, Gross M, Jaffe CA et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 1999; 54: 607 – 11
dc.identifier.citedreferenceShahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154 – 64
dc.identifier.citedreferenceGreenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90: 6410 – 7
dc.identifier.citedreferenceMorgans AK, Fan KH, Koyama T et al. Bone complications among prostate cancer survivors: long‐term follow‐up from the prostate cancer outcomes study. Prostate Cancer Prostatic Dis 2014; 17: 338 – 42
dc.identifier.citedreferenceShao YH, Moore DF, Shih W, Lin Y, Jang TL, Lu‐Yao GL. Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU Int 2013; 111: 745 – 52
dc.identifier.citedreferenceBae DC, Stein BS. The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate. J Urol 2004; 172: 2137 – 44
dc.identifier.citedreferenceBienz M, Saad F. Androgen‐deprivation therapy and bone loss in prostate cancer patients: a clinical review. Bonekey Rep 2015; 4: 716
dc.identifier.citedreferenceSaad F, Adachi JD, Brown JP et al. Cancer treatment‐induced bone loss in breast and prostate cancer. J Clin Oncol 2008; 26: 5465 – 76
dc.identifier.citedreferenceSkolarus TA, Caram MV, Shahinian VB. Androgen‐deprivation‐associated bone disease. Curr Opin Urol 2014; 24: 601 – 7.
dc.identifier.citedreferenceZhumkhawala AA, Gleason JM, Cheetham TC et al. Osteoporosis management program decreases incidence of hip fracture in patients with prostate cancer receiving androgen deprivation therapy. Urology 2013; 81: 1010 – 5
dc.identifier.citedreferenceGralow JR, Biermann JS, Farooki A et al. NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw 2009; 7 ( Suppl. 3 ): S1 – 32; quiz S33‐35.
dc.identifier.citedreferenceTanvetyanon T. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer 2005; 103: 237 – 41
dc.identifier.citedreferenceShahinian VB, Kuo YF. Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer. J Gen Intern Med 2013; 28: 1440 – 6
dc.identifier.citedreferenceMorgans AK, Smith MR, O’Malley AJ, Keating NL. Bone density testing among prostate cancer survivors treated with androgen‐deprivation therapy. Cancer 2013; 119: 863 – 70
dc.identifier.citedreferenceSuarez‐Almazor ME, Peddi P, Luo R, Nguyen HT, Elting LS. Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapy. Supp Care Cancer 2014; 22: 537 – 44
dc.identifier.citedreferenceWilcox A, Carnes ML, Moon TD et al. Androgen deprivation in veterans with prostate cancer: implications for skeletal health. Ann Pharmacother 2006; 40: 2107 – 14
dc.identifier.citedreferenceChang P, Regan MM, Ferrer M et al. Relief of urinary symptom burden after primary prostate cancer treatment. J Urol 2017; 197: 376 – 84
dc.identifier.citedreferenceBass E, Campbell RR, Werner DC, Nelson A, Bulat T. Inpatient mortality of hip fracture patients in the Veterans Health Administration. Rehabil Nurs 2004; 29: 215 – 20
dc.identifier.citedreferenceSmith MR, Egerdie B, Hernandez Toriz N et al. Denosumab in men receiving androgen‐deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745 – 55
dc.identifier.citedreferenceCharlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373 – 83
dc.identifier.citedreferenceQuan H, Sundararajan V, Halfon P et al. Coding algorithms for defining comorbidities in ICD‐9‐CM and ICD‐10 administrative data. Med Care 2005; 43: 1130 – 9
dc.identifier.citedreferenceStratton J, Hu X, Soulos PR et al. Bone density screening in postmenopausal women with early‐stage breast cancer treated with aromatase inhibitors. J Oncol Pract 2017; 13: e505 – 15
dc.identifier.citedreferenceTheriault RL, Biermann JS, Brown E et al. NCCN Task Force Report: Bone Health and Cancer Care. J Natl Compr Canc Netw 2006; 4 ( Suppl. 2 ): S1 – 20; quiz S21‐22.
dc.identifier.citedreferenceSaylor PJ, Smith MR. Bone health and prostate cancer. Prostate Cancer Prostatic Dis 2010; 13: 20 – 7
dc.identifier.citedreferenceMoyer VA, U.S. Preventive Services Task Force. Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013; 158: 691 – 6
dc.identifier.citedreferenceSaylor PJ. Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer. Asian J Androl 2014; 16: 341 – 7
dc.identifier.citedreferenceNational Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer v2.2017. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed June 2017.
dc.identifier.citedreferenceIto K, Elkin EB, Girotra M, Morris MJ. Cost‐effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med 2010; 152: 621 – 9
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
bju14075.pdf
Size:
253.1KB
Format:
PDF
View/Open
Name:
bju14075_am.pdf
Size:
263.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.